Oruka Therapeutics Insider Sale Puts Clinical-Stage Biotech Sentiment Under the Microscope
Oruka’s $853,985 insider sale draws attention as traders weigh the transaction against positive EVERLAST-B Phase trial results.
PMV Pharmaceuticals’ Updated Rezatapopt Data Puts Precision Oncology Back in Focus
PMV Pharmaceuticals’ updated PYNNACLE Phase 2 data gives investors a closer look at rezatapopt and i…
Revolution Medicines Defies Market Selloff as Survival Data Lift RVMD
RVMD traded higher as survival data, a $226 William Blair target and new Phase 3 treatment activity …
Belite Bio Slides 12% as FDA Extends Tinlarebant Review
Belite Bio shares fell 12% after the FDA extended its tinlarebant review by three months, resetting …
Savara Shares Slip After FDA Delays Autoimmune PAP Decision
Savara’s missed FDA target date leaves investors facing a longer wait for clarity on its autoimmune …
Revolution Medicines Rallies on Clinical Data as Biotech Decouples From Weak Market
Revolution Medicines showed premarket relative strength as clinical data offset a 1.0% S&P 500 decli…
Capricor Therapeutics Defies Market Selloff as Traders Position for FDA Catalyst
CAPR rallied in premarket trading as the Nasdaq and S&P 500 declined, putting the biotech’s FDA cata…
Alnylam’s $25 Million Regeneron Milestone Puts Its RNAi Model in Focus
Alnylam’s $25 million Livsayis milestone highlights the commercial value of its RNAi platform and pa…
Black Diamond Gains as FDA Maps Accelerated-Approval Path for Silevertinib
FDA guidance on accelerated approval and a broad EGFR mutation definition may reduce uncertainty aro…
J&J Seeks FDA Approval to Expand CAPLYTA Into Bipolar Mania
J&J’s CAPLYTA filing could create a fifth potential indication, broadening its psychiatric franchise…